Moonlake Immunotherapeutics reported 16-week results from its two identically designed Phase 3 VELA trials of sonelokimab in moderate-to-severe hidradenitis suppurativa. VELA-1 achieved statistical significance on the high-bar HiSCR75 primary endpoint and all key secondaries. VELA-2 missed the Week 16 primary analysis under the pre-specified composite strategy, attributed to a higher-than-expected placebo response and intercurrent events, but met the primary and all key secondary endpoints under the pre-specified treatment-policy strategy. Across the combined program, sonelokimab delivered clinically meaningful gains in lesion reduction, pain, and quality of life, with a favorable safety profile and no new signals. The company will advance to the pre-specified 52-week readout and engage regulators to confirm a registration path.
The strategic bet to anchor Phase 3 on HiSCR75—rather than the more widely used HiSCR50—aims squarely at differentiation. If accepted by regulators, it could strengthen label language, payer positioning, and HCP confidence by aligning efficacy claims to a higher threshold of disease control. The VELA-2 composite miss, however, introduces filing ambiguity. Regulators embracing the ICH E9(R1) estimand framework may accept convergent evidence across both analysis strategies, but inconsistency on the primary estimand demands a clear narrative on intercurrent events, site conduct, and the operational drivers of placebo performance.
Why this matters now is straightforward: HS remains a high-burden, under-treated inflammatory disease where therapeutic momentum is shifting toward IL-17 pathway modulation. In VELA-1 and VELA-2, sonelokimab reached HiSCR75 rates of roughly 35% at Week 16 versus placebo rates of 18% and 26%, respectively, under the treatment-policy strategy, with parallel gains on HiSCR50 and IHS4-55. Pain relief showed a roughly twofold advantage over placebo based on a three-point NRS improvement, and nearly 60% of treated patients achieved a meaningful DLQI gain. Safety tracked the IL-17 class, including oral candidiasis, without new signals such as IBD or suicidal ideation. For patients and prescribers, the early onset of effect by Week 4 and a practical regimen—120 mg subcutaneous with biweekly induction to Week 6 and monthly maintenance at a 1 mL volume—supports adoption if access is secured. For payers, the higher efficacy threshold, pain and quality-of-life data, and month-to-month maintenance dosing are the levers that will determine value perception.
The outlier placebo response in VELA-2 is a reminder of dermatology’s growing placebo volatility and the importance of estimand planning, site management, and intercurrent-event handling in pivotal trials. It also highlights a broader market reality: as more sponsors elevate endpoints to command premium positioning, the burden of statistical coherence and operational rigor rises. For Medical Affairs, this places a premium on clear education around HiSCR75, tunnel and nodule dynamics, and real-world functional outcomes, alongside rapid RWE generation to support payer and guideline uptake.
Commercially, Moonlake sits at the nexus of two trends: class consolidation around IL-17 biology in immuno-dermatology and renewed appetite for late-stage, de-risking assets in biotech M&A and partnering. The adolescent HS study, 52-week durability, and broader psoriatic arthritis program expand optionality, but the registrational strategy in HS—whether to file on the totality of Week 16 evidence or await 52-week data—will define near-term trajectory.
The next signal to watch is whether Week 52 shows sustained HiSCR75, deeper tunnel resolution, and maintained safety, and whether regulators endorse HiSCR75 as the benchmark that payers and competitors must now meet.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
